Regular ArticleNonreplicating Recombinant Vaccinia Virus Encoding Human B-7 Molecules Elicits Effective Costimulation of Naive and Memory CD4+T Lymphocytesin Vitro☆,☆☆
References (26)
- et al.
Immunity
(1995) - et al.
Cell
(1995) - et al.
Immunity
(1994) - et al.
Immunity
(1994) - et al.
Virology
(1990) - et al.
J. Mol. Biol.
(1989) - et al.
Cell
(1990) - et al.
Proc. Natl. Acad. Sci. USA
(1991) - et al.
J. Immunol.
(1989) - et al.
Science
(1993)
Proc. Natl. Acad. Sci. USA
Nature
Cited by (17)
Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma
2010, Molecular TherapyCitation Excerpt :The rVV used in this trial (Figure 1a) was produced and tested according to GMP (Good Manufacturing Practice) standards (BioReliance, Stirling, UK). The capability of this replication-incompetent rVV to induce the expression of surface markers, the presentation of each recombinant epitope, and to stimulate specific CD8+ CTL responses have been verified “in vitro” and “in vivo”, as previously reported.21,24,38 GMP grade synthetic peptides, corresponding to the three transgenic epitopes under investigation, resuspended in phosphate buffered saline (PBS)–20% dimethyl sulfoxide, were commercially obtained (Orpegen Therapeutica, Heidelberg, Germany).
Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial
2008, Contemporary Clinical TrialsCitation Excerpt :We demonstrated in preclinical studies that endoplasmic reticulum targeted minigene products represent highly immunogenic formulations of antigenic epitopes [48,49]. Co-expression of T-cell co-stimulatory molecules by the same recombinant vector did further improve CTL induction, even in the absence of classical antigen presenting cells [50–52]. Hence, we developed a rVV encoding 3 melanoma associated HLA-A0201 restricted epitopes (Melan-A/Mart-127-35, GP100280-288 and Tyrosinase1-9) in the form of minigenes that included an individual viral promoter together with the adenovirus E3/19K signal peptide, driving the resulting fusion product into the endoplasmic reticulum [53], thereby bypassing discrete steps of antigen processing.
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): Enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
2005, BloodCitation Excerpt :The ability of 2 replication-defective vaccinia-derived vectors, (1) a psoralen-UV–inactivated rV-TRICOM (designated as PUVA-rV-TRICOM) and (2) the replication-defective MVA-TRICOM vector, to infect CLL cells and to enhance their immunogenicity was also studied. Psoralen and UV light treatment to inactivate vaccinia has been used in vitro and in vivo as a procedure to improve safety of vaccinia virus vectors30,34,35 and was previously reported not to eliminate expression of recombinant genes driven by early promoters.36 An initial comparison using 10, 20, and 40 MOI of PUVA-rV-TRICOM for CLL infection showed similar induction of transgene expression, and all subsequent experiments used 10 MOI of PUVA-rV-TRICOM.
- ☆
APC, antigen presenting cellCPE, cytopathic effect; CTL, cytotoxic lymphocyte; FCS, fetal calf serum; m.o.i., multiplicity of infection; PBMC, peripheral blood mononuclear cells; PFU, plaque forming unit; PLWUV, Psoralen and long-wave UV light; PMA, phorbol-12-myristate-13-acetate; rec, recombinant; TCR, T-cell receptor; VV, Vaccinia virus;
- ☆☆
F. M. AusubelR. BrentR. E. KingstonD. D. MooreJ. G. SeidmanJ. A. SmithK. Struhl, Eds.
- 1
To whom correspondence should be addressed at Research Unit, Department of Surgery, ZLF Lab 404, Hebelstrasse 20, CH-4031 Basel, Switzerland. Fax: +41 61 265 3990.